The company offers comprehensive contract development and manufacturing organization (CDMO) and contract research organization (CRO) solutions to accelerate drug development journeys. Their capabilities span small and large molecules, advanced therapies like viral vectors, cell therapy, and mRNA, and steriles. Patheon delivers complete end-to-end CDMO capabilities for small molecules, large molecules, advanced therapies, clinical trials, and commercial services to help move from molecule to medicine to market.
Patheon benefits from Thermo Fisher Scientific's $7.2 billion (August 2017) acquisition, providing substantial capital and scale. As a leading global CDMO with 60+ facilities and advanced therapy capabilities including mRNA and cell therapy, it commands strong market positioning. While specific recent financial metrics are limited in available data, the company's integration into Thermo Fisher's life sciences portfolio and continued expansion signal operational strength.
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.
Open report →